Source:http://linkedlifedata.com/resource/pubmed/id/20408110
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2010-9-20
|
| pubmed:abstractText |
We assessed the pattern of levo-thyroxine (l-thyroxine) therapy in very premature newborns over a 10-year period. We analyzed the electronic database of a large private neonatal practice group (Pediatrix, Ft. Lauderdale, FL) for 23- to 32-week gestation neonates ( N?=?96,813) managed during 1997 to 2006. L-thyroxine use was analyzed by birth year and by gestational age (GA). L-thyroxine use increased with decreasing GA (nadir 0.3% at 32 weeks, peak 8.4% at 24 weeks). L-thyroxine supplementation increased 2.6-fold over time among infants ?26 weeks' GA (3.4% in 1997 to 1999 to 8.7% in 2004 to 2006), but did not change among infants born at ?29 weeks' GA. The highest rate of l-thyroxine supplementation (12.8%) occurred among 24-week GA infants in 2006. Median age at start of l-thyroxine was 23 days (25 to 75%, 15 to 38 days). Only 2% of treated infants were started on day of life 1. Despite no clear evidence from randomized trials supporting thyroid supplementation, l-thyroxine treatment of very preterm infants has significantly increased over the past decade. As l-thyroxine treatment was not consistent with protocols from published randomized trials, new focused randomized controlled trials are needed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1098-8785
|
| pubmed:author | |
| pubmed:copyrightInfo |
© Thieme Medical Publishers.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
731-5
|
| pubmed:meshHeading |
pubmed-meshheading:20408110-Child,
pubmed-meshheading:20408110-Child, Preschool,
pubmed-meshheading:20408110-Congenital Hypothyroidism,
pubmed-meshheading:20408110-Developmental Disabilities,
pubmed-meshheading:20408110-Hormone Replacement Therapy,
pubmed-meshheading:20408110-Humans,
pubmed-meshheading:20408110-Infant,
pubmed-meshheading:20408110-Infant, Newborn,
pubmed-meshheading:20408110-Infant, Premature,
pubmed-meshheading:20408110-Nervous System Diseases,
pubmed-meshheading:20408110-Randomized Controlled Trials as Topic,
pubmed-meshheading:20408110-Retrospective Studies,
pubmed-meshheading:20408110-Thyroxine
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Increasing supplemental thyroid hormone use among premature infants born at 23 to 32 weeks' gestation.
|
| pubmed:affiliation |
Department of Pediatrics, University of Utah, Salt Lake City, Utah 84158-1289, USA.
|
| pubmed:publicationType |
Journal Article
|